CAI · Earnings event · Q2 2026 · archived
Caris Life Sciences (CAI) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS — vs estimate $0.01 (-100.0%) — classified UNKNOWN.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $0.01 | — | -100.0% |
| Revenue (2026-06-30) | — | $263.7M | — |
Revenue source: xbrl.
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated CAI Hold at 6.8/10. After the Q2 2026 report, the verdict moved to Buy (Wait) at 6.7/10.
Healthcare context
CAI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $6.16B
- P/E (fwd)
- 57.7
- P/E (ttm)
- 2.3
- 52-week range
- $14.19–$42.50
- Off 52-week high
- 48.7%
- RSI (14)
- 79
- Volume vs avg
- 0.80×
- Engine score
- 6.0/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.